



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

MRTX-1257

Cat. No.: HY-114436
CAS No.: 2206736-04-9
Molecular Formula: C₃₃H₃₉N₇O₂
Molecular Weight: 565.71
Target: Ras
Pathway: GPCR/G Protein
Storage: -20°C, stored under nitrogen
 * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 55 mg/mL (97.22 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM		1.7677 mL	8.8385 mL	17.6769 mL
		5 mM		0.3535 mL	1.7677 mL	3.5354 mL
		10 mM		0.1768 mL	0.8838 mL	1.7677 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (4.42 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.5 mg/mL (4.42 mM); Suspended solution; Need ultrasonic					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (4.42 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	MRTX-1257 is a selective, irreversible, covalent and orally active KRAS G12C inhibitor, with an IC ₅₀ of 900 pM for KRAS dependent ERK phosphorylation in H358 cells ^[1] .
IC ₅₀ & Target	KRAS(G12C)
In Vivo	MRTX-1257 (1 mg/kg, 3 mg/kg, 10 mg/kg, 30 mg/kg and 100 mg/kg, orally, daily for 30 days) shows rapid tumor growth inhibition at all dose groups in MIA PaCa-2 G12C Xenograft model in mice ^[1] . ?MRTX-1257 shows sustained regression at 3,10, 30, and 100 mg/kg dose groups ^[1] . ?MRTX-1257 dosed of 100 mg/kg daily leads to complete responses that are maintained >70 days after cessation of

treatment^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	MIA PaCa-2 G12C Xenograft Model (mouse) ^[1] .
Dosage:	1 mg/kg, 3 mg/kg, 10 mg/kg, 30 mg/kg and 100 mg/kg.
Administration:	Orally daily for 30 days.
Result:	Shown rapid tumor growth inhibition at all dose groups. Shown sustained regression at 3,10, 30, and 100 mg/kg dose groups. 100 mg/kg daily led to complete responses that are maintained >70 days after cessation of treatment.

CUSTOMER VALIDATION

- J Am Chem Soc. 2022 Sep 19.
- J Proteome Res. 2021 Nov 9.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Matthew et al. Structure-Based Drug Discovery of MRTX1257, a Selective, Covalent KRAS G12C Inhibitor with Oral Activity in Animal Models of Cancer.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA